Researchers also adjusted their analysis to prove that the change in CDLQI score between treatment type was independent of PASI score improvement, as systemic therapies are known to achieve higher PASI responses. They also adjusted for age, sex, disease duration and treatment duration.
“The weaker association between topical treatment and improvement in QOL might be attributed to several characteristics of topical agents, such as time taken to apply ointments, odors, and stickiness,” the authors propose, although they did not perform any investigation into specific advantages or disadvantages to any treatment type in regard to QOL impact.
Ultimately, this study suggests that reaching PASI 90 or greater and reducing BSA involvement may be worthwhile treatment goals for dermatologists and their pediatric patients – and systemic treatments, both conventional and biological, may offer the most realistic means to achieving optimal QOL.
1. Bruins FM, Bronckers IMGJ, Groenewoud HMM, et al. Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients. JAMA Dermatol. 2019;
2. Langley RG, Paller AS, Hebert AA, et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol. 2011;64(1):64-70.